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A B S T R A C T
The anterior nucleus of the thalamus (AN) has been suggested as a potential target for seizure
modulation in animal models and patients with refractory epilepsy. We investigate whether
microinjections of GABAergic agonists into the AN were protective against pilocarpine-induced
generalized seizures and status epilepticus (SE). Rats were treated with bilateral AN injections of
muscimol (160 or 80 nmol), bicuculline (15 nmol), or saline (controls) 20 min prior to pilocarpine
administration (350 mg/kg i.p.). Electrographic recordings were used to conﬁrm seizure activity. We
found that pretreatment with AN muscimol 160 nmol increased the latency to seizures and SE by 2.5–
3.0-fold. This dose however was associated with side effects, particularly hypotonia. AN bicuculline was
proconvulsant, whereas no major effect was observed after muscimol 80 nmol injections. The
percentage of animals that developed SE was similar across groups. Overall, microinjection of high doses
of muscimol into the AN delayed the occurrence of pilocarpine-induced seizures and SE but was not able
to prevent these events.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The anterior nucleus of the thalamus (AN) occupies a central
position in limbic circuits and has been suggested as a potential
target for seizure modulation in animal models and patients with
refractory epilepsy.1–10 In rodents, anticonvulsant effects have
been observed with different local AN interventions, including
lesions, high frequency stimulation and the microinjection of
GABAergic agonists.2,5–7,10–13 In a previous report, we have
compared the effects of AN thalamotomies and stimulation in
the pilocarpine model of epilepsy.2 While lesions were extremely
effective against seizures and status epilepticus (SE), stimulation
only prolonged the latency to these events.2 As AN thalamotomies
have been associated with signiﬁcant memory disturbance,14,15
alternative therapeutic strategies leading to an anticonvulsant
outcome are still needed. In the pentylenetetrazol (PTZ) model, the
injection of GABAergic agonists into the AN were partially* Corresponding author at: Division of Neurosurgery, Toronto Western Hospital,
399 Bathurst StreetWW4-437,M5T2S8 Toronto, ON, Canada. Tel.: +1 416 6035771;
fax: +1 416 6035298.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.02.010protective against seizures.5,6We investigate whether GABAergic
agonists microinjected into the AN are also protective against
pilocarpine-induced seizures and SE.
2. Methods
2.1. Animal groups
Animals were divided into 4 groups: (1) muscimol 160 nmol;
(2) muscimol 80 nmol; (3) bicuculline 15 nmol; or (4) saline
(controls). These doses were chosen as they have been previously
shown to inﬂuence seizure activity in the PTZmodel.6 All protocols
were approved by the Research Ethics Board of the Federal
University of Sa˜o Paulo (Universidade Federal de Sa˜o Paulo).
2.2. Stereotactic procedures
Adult male Wistar rats (250–300 g) were anesthetized with
ketamine/xylazine (100/7.5 mg/kg intraperitoneally; i.p.) and had
their heads ﬁxed to a stereotactic apparatus (Model 900, David
Kopf Instruments). Stainless steel guide cannulae (21 G; 10 mm of
length) were bilaterally implanted into the AN at the following
coordinates relative to the bregma: anteroposterior (AP) 1.4,vier Ltd. All rights reserved.
Fig. 1. Location of the cannulae used for microinjecting GABAergic agents into the
anterior nucleus of the thalamus (AN). Schematic representation of the tips of the
cannulae though which 0.5 ml of muscimol 160 nmol ( ), muscimol 80 nmol ( ),
or bicuculline ( ) were successfully injected within the AN (reprinted from Ref. 16;
p. 23–26; Copyright (1998) with permission from Elsevier). Cannulae placement in
animals receiving 0.2ml injections was similar to that represented in this ﬁgure.
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per groupwere implantedwith two stainless steel epidural screws for
electrographic recordings (AP +0.4, ML 1.4 and AP 3.0, ML 3.4 to the
right).16 Guide cannulae and epidural electrodes were ﬁxed to the
skull with dental acrylic cement. At the end of the procedures, 30 G
stainless steel stylets were inserted into the cannulae to avoid
obstruction. One concern when drug injections are carried out in the
dorsal thalamus is that an eventual extravasation to the lateral
ventricle might interfere with outcome. To assess the effects of
ventricular muscimol injections, a different group of animals was
implantedwith ventricular cannulae (AP0.8, ML 1.4 to the right at a
depth of 3.4 mm).16
2.3. Intraparenchymal drug administration, pilocarpine injections
and ictal assessment
Experiments were conducted 5–7 days after surgeries. Animals
were initially provided methylscopolamine (1 mg/kg i.p.) to block
the undesirable peripheral effects of pilocarpine. Ten minutes later,
they receivedmuscimol, bicuculline or saline bilaterally into the AN.
Muscimol (160 or 80 nmol; Research Biochemicals International)
was dissolved in 0.5 or 0.2ml of a 2% Evans blue saline solution. To
dissolve bicuculline (Research Biochemicals International, Natick,
MA) glacial acetic acidwas used. The solution was titrated to pH 6.0
with1NaOHandsubsequentlybroughtup toavolumeof0.5mlwith
2% Evans blue saline, similar to previous reports.6 Control animals
received 0.5 or 0.2ml of a 2% Evans blue saline solution.
Microinjection of the drugs was carried out with a Hamilton
syringe, connected via a silicon tube to a blunt tip 30 G stainless
steel needle (11 mm of length). Just before the administration of
the drugs, the stylets were removed from the guide cannulae and
the 30 G needle inserted in place. As the needlewas longer than the
cannulae, the last millimeter of its tip protruded to the brain
parenchyma. Injections were done over 1 min and the needle was
left in place for an additional minute. Thereafter, the needle was
removed and the stylet reinserted into the guide cannulae. The
procedure was then repeated in the contralateral side.
Pilocarpine (350 mg/kg i.p. in a single bolus injection)was given
to the animals 30 min after methylscopolamine (20 min after the
beginning of the intraparenchymal administration of the drugs).
The following variables were assessed: (1) latency to the ﬁrst
behavioral generalized seizure (time elapsed from pilocarpine
administration to the ﬁrst behavioral generalized seizure); (2)
latency to SE (time elapsed from pilocarpine administration to the
momentwhen behavioral seizures became uninterrupted); and (3)
percentage of animals that developed SE.
After pilocarpine administration commonly observed ictal
manifestations include a motionless state, orofacial automatisms,
forelimb clonus, and generalized tonic and/or clonic events, which
ultimately lead to rearing and falling.17,18 For the purpose of this
study, we have only recorded behavioral seizures characterized by
clonic, tonic, or tonic–clonic movements leading to rearing and/or
falling.
2.4. EEG analysis and histology
EEG analysis was conducted using a bipolar montage (cortical
screw 1 vs. 2). Signals were recorded using an Embla unit (Embla
N7000, Iceland) from baseline (5 min prior to the pharmacological
experiments) to the development of SE. Electrographic analysis
was conducted just to corroborate behavioral ﬁndings.
To assess the location of the guide cannulae and injection sites,
animals were sacriﬁced by deep anesthesia with thiopental
(60 mg/kg i.p.), followed by transcardiac perfusion with 0.9%
saline and 10% formaldehyde. Coronal sections with a 24-mm
thickness were cut on a cryostat, collected in phosphate buffer,mounted on glass slides, and stained with cresyl violet. Only
animals with injections in the AN were considered in this study
(Fig. 1). Overall, a total of 68 rats were used, 5 of which ended up
with misplaced cannulae.
2.5. Statistical analysis
One-way ANOVA (post hoc Tukey HSD) and Chi2 tests were
used to compare data across groups. Statistical signiﬁcancewas set
at p = 0.05. p-Values along the text are post hoc comparisons of
experimental animals and controls.
3. Results
3.1. AN 0.5ml muscimol and bicuculline injections
We found that AN muscimol injections were able to modulate
seizure activity induced by acute pilocarpine administration. This
was particularly due to the group receiving 160 nmol (n = 6), which
had a 2–3-fold increase in the latency to seizures and SE (p < 0.001
Fig. 2. GABAergic agents microinjected into the anterior nucleus of the thalamus
(AN) inﬂuence the development of pilocarpine-induced seizures and status
epilepticus (SE). (A and B) Animals receiving AN 160 nmol muscimol 0.5ml
injections (n = 6) had a signiﬁcantly increased latency to seizures and SE as
compared to controls (n = 8; p < 0.001 and p = 0.01). In contrast, 80 nmol muscimol
injections (n = 6) were not protective, whereas AN bicuculline (n = 5) was
proconvulsant. (C) No signiﬁcant differences were observed in the percentage of
animals developing SE across groups. Lines on top of the bars represent standard
deviations. *Statistically signiﬁcant.
Fig. 3. Latency for pilocarpine-induced seizures and status epilepticus (SE) in
animals treatedwith anterior thalamic nucleus (AN) or ventricular 0.2 ml muscimol
injections. (A and B) Animals receiving AN 160 nmol muscimol (n = 11) had a
signiﬁcantly increased latency to seizures and SE as compared to controls (n = 10;
p < 0.01 and p = 0.02). (C) In contrast, injections of 64–80 nmol (n = 4) or 100–
120 nmol (n = 4) of ventricular muscimol were not protective. Lines on top of the
bars represent standard deviations. *Statistically signiﬁcant.
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and p = 0.2; n = 6) were not protective, while AN bicuculline (p = 0.1
and p = 0.09; n = 5) was proconvulsant (Fig. 2). As all bicuculline
treated animals died a few minutes after status, we decided not to
pursue further experiments with this drug (e.g. to increase the
sample size for reaching statistical signiﬁcance).Of note,mortality in
our study has only occurred after pilocarpine administration. No
animal has died before or after thalamic injections.
Rats receiving muscimol 160 nmol and pilocarpine developed
side effects approximately 25–30 min after AN injections (5–
10 min following pilocarpine administration). These were mainly
characterized by a change in posture (spreading the hindlimbs far
apart) and some degree of hypotonia. This pattern of adverse
events was noticed in all animals receiving muscimol 160 nmol,
independent on the site of injections (e.g. anterodorsal (AD),
anteroventral (AV) or anteromedial thalamic nuclei (AM)). Of note,
side effects were not observed in animals given AN muscimol
160 nmol without pilocarpine (n = 3), suggesting that toxicity was
likely a consequence of the interaction between treatments.
3.2. Animals treated with 0.2ml AN injections and ventricular
muscimol
To rule out that outcome after ANmuscimol injections was due
to an eventual ventricular extravasation of the drugwe (1) injecteda group of animals with smaller volumes of AN muscimol and (2)
characterized the effects of ventricular muscimol injections.
As in our initial experiments, latency to seizures and SE in
animals receiving 0.2 ml ofmuscimol 160 nmol into the AN (n = 11)
was signiﬁcantly increased as compared to controls (p < 0.01 and
p = 0.02; n = 10; Fig. 3A and B). Side effects in this group occurred in
all animals and were similar to those after 0.5 ml injections.
Muscimol ventricular injections (0.2 ml) were conducted
unilaterally at the following concentrations: 64–80 nmol (n = 4),
100–120 nmol (n = 6), 160 nmol (n = 4). Those were chosen as they
would correspond to a hypothetical ventricular extravasation of
20–25, 30–40 or 50% of the bilateral 160 nmol AN injections.
Animals given 100–120 nmol of ventricular muscimol with no
pilocapine (n = 2) developed a speciﬁc pattern of side effects that
was different from that observed in AN treated groups. Approxi-
mately 10–15 min after the injections, they became slightly
hypotonic, moving slowly in circles around the cage. This was
followed by a state of decreased responsivity to external stimuli,
which lasted a few hours. Once the animals recovered, they
developed signiﬁcant hyperphagia. No adverse effects were
observed after 64–80 nmol injections, while 160 nmol ofmuscimol
into the ventricle was associated with severe hypotonia and
respiratory arrest in 5 min.
Neither 100–120 nmol (n = 4) nor 64–80 nmol of ventricular
muscimol (n = 4) were protective against pilocarpine-induced SE
(Fig. 3C). The pattern of side effects in these animals was similar to
that described above.
Fig. 4. Electrographic activity recorded in the cerebral cortex after pilocarpine
treatment. EEG tracings showing the onset of a generalized seizure in animals
treated with bilateral AN injections of saline (upper trace in A) or muscimol
160 nmol (upper trace in B). In both groups, status epilepticus was characterized by
continuous high-voltage fast spiking activity (lower traces in A and B). Vertical scale
bar, 100 mV; horizontal scale bar, 5 s.
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As previously mentioned, EEG recordings in our study were
only carried out to show that the events characterized behaviorally
were actual seizures and SE. In saline-treated controls and animals
that had AN muscimol 160 or 80 nmol injections, seizures were
characterized by repetitive high-voltage fast spiking discharges. SE
was characterized by continuous high-voltage fast spiking activity
(Fig. 4).
3.4. Misplaced injections
Misplaced injections were documented in 5 animals. Three
received eithermuscimol 160 nmol (n = 1) or 80 nmol (n = 2) in the
border of the reticular nucleus and nucleus reuniens. None had an
anticonvulsant effect. One animal received 160 nmol of muscimol
unilaterally into the AN with the contralateral injection spilling
over to the ventricle. It developed severe hypotonia immediately
after the injection and died within minutes. The other animal had
bicuculline injected in one of the ventricles, developing violent
tonic seizures within minutes and dying soon after.
4. Discussion
We found that AN muscimol injections were somewhat
protective against pilocarpine-induced seizures and SE. This
however, was only observed at doses associated with adverse
effects.
Our results are in line with previous work in other animal
models of epilepsy. In a series of publications, Mirski and
colleagues have shown that AN muscimol injections reduced
PTZ electrographic seizures, whereas AN g-vinyl-GABA (inhibitor
of GABA transaminase) decreased the number of animals devel-
oping clinical seizures.5,6 In contrast, AN injections of g-vinyl-
GABA were not protective against maximal electroshock-induced
seizures.5 In addition to the AN, the intraparenchymal adminis-
tration of GABAergic agonists in nearby thalamic targets, including
the mediodorsal, reuniens/rhomboid, and anterior intralaminar
nuclei, has also been shown to modulate seizure activity in
different models of epilepsy.19–23Different agents have been
shown to induce convulsive states in rodents. We have chosen
pilocarpine because, in addition to its well-established validity as a
model, it has been used in our former studies to assess the role of
AN radiofrequency lesions and DBS against seizures and SE.2,10
Though the mechanisms of epileptogenesis following pilocarpine
are still unclear, the primary sites of action of this cholinergiccompound seem to be cerebral structures containing a high
concentration of muscarinic receptors.24 As the AN is one of such
regions,25,26 it would be conceivable to hypothesize that muscimol
injections could disrupt the propagation of ictal activity to limbic
circuits. In humans, AN DBS has been suggested to be particularly
effective against partial and secondary generalized seizures.1,4,8,9
Bearing in mind the AN connectivity, future investigation is still
needed to clarify whether the efﬁcacy of interventions within this
nucleus would improve with the use of models characterized by a
more focal induction of limbic seizures (i.e. kindling in the
amygdala or intrahippocampal kainic acid injections).
One of the potential drawbacks of studies investigating the
effects of intraparenchymal drug administration in the dorsal
thalamus is the diffusion of the compounds into adjacent structures,
including the ventricles. Though we cannot fully rule out this
possibility,we ﬁnd it to be unlikely for several reasons: (1) a smaller
volume of drug injected into the AN led to a similar outcome as
compared to 0.5ml injections, (2) the pattern of adverse events in
animals receiving muscimol in all subdivisions of the AN was fairly
similar (even with the AM being relatively far from the thalamic/
ventricular border), (3) side effects in animals receiving ventricular
muscimolweredifferent fromthose in theANgroups, (4) ventricular
muscimol injections were not protective against seizures and SE,
even at toxic doses. Altogether, these ﬁndings suggest that the
anticonvulsant effects of ANmuscimol in our study were likely due
to a local effect of the drug within the thalamus.
Taking into account the considerations above, it is important to
discuss potential sites of action of muscimol within the AN. Most
cells in this nuclear complex are immunocytochemically positive
for glutamate and aspartate.27 GABAergic neurons comprise a
minor population, which has mainly been described in the AD.27,28
Similarly, GABAergic terminals are primarily found in AD, but also
in AV and AM.27–29 In rats, these are mainly associated with
afferent projections from the rostral portion of the thalamic
reticular nucleus.30,31 In this context, one might suggest that
muscimol primarily affected AN cells receiving innervation from
either the reticular nucleus or local circuit interneurons. Whether
this mechanism is actually responsible for the anticonvulsant
effects of AN muscimol injections remains to be demonstrated.
We have so far investigated the effects of electrical stimulation,
lesions and the topical administration of drugs into the AN of
pilocarpine treated rats. Even though a direct comparison across
techniques has not been conducted, results obtained after AN
160 nmol muscimol injections were similar in magnitude to those
previously described with AN stimulation.2,10 Muscimol is a
GABAergic agonist that leads to a chemical inactivation of cell
bodies nearby the injections. In contrast, commonly accepted
mechanisms of DBS comprise not only a depolarization block of
local neuronal populations but also the activation of axonal
pathways nearby the electrodes.32,33 In this context, one could
hypothesize that the functional inactivation of the AN may be an
important feature for the increase in latency to pilocarpine-
induced seizures and SE after either stimulation or muscimol
injections.
In summary, we found that the local administration of high
doses of muscimol into the AN delayed the occurrence of
pilocarpine-induced seizures and SE. The impact of this treatment
in the duration of seizures is still unknown and remains to be
elucidated. So far, the only therapy capable of hindering these
events in our series of experiments in the pilocarpine model of
epilepsy was AN thalamotomy.2 This treatment however, did not
lead to a signiﬁcant reduction in seizure frequency in chronic
epileptic animals34 and is known to cause signiﬁcant memory
disturbance.14,15 Additional investigation to characterize suitable
treatmentmodalities to prevent/block seizure activitywith limited
adverse effects is still necessary.
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